Results - Announcements
Aarti Drugs Ltd share price gained 2.60% to Rs 465.6 after the company's net profit saw a strong growth of 65.11% to Rs 82.77 crore, while revenue from operations increased 17.57% to Rs 826.24 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.73 lakh crore, rising 5.41%. It has improved by 1.84% over last one week and gained upto 1.37% in last one month while the market capitalization of Aarti Drugs Ltd has marginally improved by 4% and 13.30% in the same period respectively.
Profit before tax (PBT) of Aarti Drugs Ltd stood at Rs 109.28 crore in Q3 FY26, jumping 80.90% year-on-year, and surging by 57.83% quarter-on-quarter. EBITDA came in at Rs 133 crore, rallying 57.75% YoY and expanding by 36.37% sequentially.
Total expenses increased by 13.94% to Rs 709.88 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 477.33 crore, posting a minor increase of 1.70% YoY, while employee benefits expense was at Rs 37.13 crore, ticking higher by 1.70% YoY.
For the TTM ended FY26, revenue from operations inched higher 7.47% to Rs 2565.31 crore, while net profit rose by 15.97% to Rs 194.94 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 28089% to Rs 306.8 crore, and PBT softened 0.41% to Rs 210.9 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 253.54 crore in FY26, as against Rs 244.58 crore in FY25.
Aarti Drugs Ltd retreated by 7.39% in last one year, outperforming the benchmark BSE Sensex which has slipped by 8.41% during the same period.
